---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-063036"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:13:56.326474+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Hepion Phase 2 ALTITUDE-NASH trial meets primary endpoint with rencofilstat 225 mg improving liver function

## Summary
- Phase 2 trial met primary endpoint: 225 mg rencofilstat reduced DSI by 1.62 units (p<0.05) and SHUNT by 2.8% (p<0.05).
- 61% of 225 mg arm achieved ≥2-point DSI improvement (p<0.05); RISK ACE reduced 1.2 events/100 pt-yrs (p<0.001).
- Secondary endpoints: ALT ↓21.6%, AST ↓4.7%, ProC3 ↓9.6%, PIIINP ↓5.6%, ELF score ↓2.5% at 225 mg (all p<0.001).
- Rencofilstat well tolerated; no drug-related SAEs; supports ongoing Phase 2b ASCEND-NASH paired biopsy trial.

## SEC filing metadata
- accession: 0001104659-23-063036
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465923063036/0001104659-23-063036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465923063036/tm2316423d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-063036
- JSON: https://secwatch.observer/filing/0001104659-23-063036.json
- Plain text: https://secwatch.observer/filing/0001104659-23-063036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.